Qi I. Wang

P.R. China
Nanning, 530021, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Enhancing HIPEC for Ovarian Cancer using Adjunctive Biomaterials.

Enhancing HIPEC for Ovarian Cancer using Adjunctive Biomaterials.

Journal: bioRxiv : the preprint server for biology

Published: November 24, 2025

Downregulation of ITIH3 contributes to cisplatin-based chemotherapy resistance in ovarian carcinoma via the Bcl-2 mediated anti-apoptosis signaling pathway.

Downregulation of ITIH3 contributes to cisplatin-based chemotherapy resistance in ovarian carcinoma via the Bcl-2 mediated anti-apoptosis signaling pathway.

Journal: Oncology letters

Published: July 12, 2022

Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma

Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma

Journal: Zhonghua fu chan ke za zhi

Published: October 25, 2017

Real-time assessment of platinum sensitivity of primary culture from a patient with ovarian cancer with extensive metastasis and the platinum sensitivity enhancing effect by metformin.

Real-time assessment of platinum sensitivity of primary culture from a patient with ovarian cancer with extensive metastasis and the platinum sensitivity enhancing effect by metformin.

Journal: Oncology letters

Published: October 10, 2017

Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo.

Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo.

Journal: OncoTargets and therapy

Published: July 15, 2017

Inhibition of enhancer of zeste homolog 2 increases the expression of p16 and suppresses the proliferation and migration of ovarian carcinoma cells in vitro and in vivo.

Inhibition of enhancer of zeste homolog 2 increases the expression of p16 and suppresses the proliferation and migration of ovarian carcinoma cells in vitro and in vivo.

Journal: Oncology letters

Published: April 15, 2017

FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells.

FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells.

Journal: Journal of ovarian research

Published: March 28, 2017

Current status and future of epithelial ovarian cancer markers

Current status and future of epithelial ovarian cancer markers

Journal: Zhonghua fu chan ke za zhi

Published: February 13, 2017

Identification of proteomic and metabolic signatures associated with chemoresistance of human epithelial ovarian cancer.

Identification of proteomic and metabolic signatures associated with chemoresistance of human epithelial ovarian cancer.

Journal: International journal of oncology

Published: May 27, 2016

Effect of MTRR gene on apoptosis and autophagy pathways in multiresistant epithelial ovarian cancer

Effect of MTRR gene on apoptosis and autophagy pathways in multiresistant epithelial ovarian cancer

Journal: Zhonghua fu chan ke za zhi

Published: April 28, 2016

Cisplatin resistant effects of dihydrofolate reductase gene expression up-regulation in epithelial ovarian cancer

Cisplatin resistant effects of dihydrofolate reductase gene expression up-regulation in epithelial ovarian cancer

Journal: Zhonghua fu chan ke za zhi

Published: February 19, 2016

Downregulation of miR-429 contributes to the development of drug resistance in epithelial ovarian cancer by targeting ZEB1.

Downregulation of miR-429 contributes to the development of drug resistance in epithelial ovarian cancer by targeting ZEB1.

Journal: American journal of translational research

Published: January 19, 2016

Showing 1-12 of 30

Last Updated: 09/26/2026